SCI Pharmtech Corp.(TW:4119)
NT$48.95-1.85 (-1.21%)
TW:4119
SCI Pharmtech Corp. financials statements
NT$48.95
At close:-1.85 (-1.21%)
SCI Pharmtech Corp. (4119) Ratios
SCI Pharmtech Corp. Ratios
TW:4119's free cash flow for Q2 2026 was NT$95.76M. For the 2026 fiscal year, TW:4119's free cash flow was decreased by NT$-60.99M and operating cash flow was NT$156.75M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.05 | 1.64 | 3.43 | 1.35 | 1.87 |
| Quick Ratio | 0.35 | 1.02 | 2.50 | 0.69 | 1.47 |
| Cash Ratio | 0.06 | 0.57 | 1.65 | 0.22 | 0.44 |
| Solvency Ratio | 0.24 | 0.45 | 0.28 | 0.30 | 0.14 |
| Operating Cash Flow Ratio | 0.21 | 0.85 | 0.38 | 0.38 | 0.37 |
| Short-Term Operating Cash Flow Coverage | 0.32 | 2.13 | 1.11 | 2.65 | -6.71 |
| Net Current Asset Value | NT$ -401.94M | NT$ -63.46M | NT$ 362.45M | NT$ -288.92M | NT$ 528.05M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.14 | 0.16 | 0.11 | 0.00 |
| Debt-to-Equity Ratio | 0.18 | 0.18 | 0.20 | 0.15 | 0.00 |
| Debt-to-Capital Ratio | 0.15 | 0.15 | 0.17 | 0.13 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.05 | 0.10 | 0.14 | 0.11 | 0.00 |
| Financial Leverage Ratio | 1.28 | 1.31 | 1.31 | 1.37 | 1.26 |
| Debt Service Coverage Ratio | 0.60 | 1.95 | 2.22 | 3.65 | -3.19 |
| Interest Coverage Ratio | 31.45 | 35.79 | 25.48 | 377.14 | 1544.02 |
| Debt to Market Cap | 0.16 | 0.09 | 0.10 | 0.06 | -0.01 |
| Interest Debt Per Share | 8.30 | 8.34 | 9.61 | 5.01 | 0.02 |
| Net Debt to EBITDA | 2.27 | 0.45 | 0.19 | 0.77 | -2.31 |
| Profitability Margins | |||||
| Gross Profit Margin | 23.78% | 26.95% | 29.09% | 32.36% | 24.08% |
| EBIT Margin | 11.55% | 44.37% | 30.77% | 13.22% | 8.52% |
| EBITDA Margin | 30.38% | 59.72% | 42.83% | 54.69% | 16.52% |
| Operating Profit Margin | 11.55% | 13.01% | 13.31% | 44.94% | 7.33% |
| Pretax Profit Margin | 7.61% | 42.45% | 30.24% | 43.10% | 7.58% |
| Net Profit Margin | 7.99% | 35.09% | 24.48% | 34.32% | 6.44% |
| Continuous Operations Profit Margin | 7.99% | 35.09% | 24.48% | 35.72% | 8.01% |
| Net Income Per EBT | 105.07% | 82.66% | 80.93% | 79.62% | 85.02% |
| EBT Per EBIT | 65.83% | 326.23% | 227.19% | 95.92% | 103.48% |
| Return on Assets (ROA) | 1.56% | 7.43% | 4.40% | 6.22% | 1.33% |
| Return on Equity (ROE) | 1.99% | 9.76% | 5.78% | 8.51% | 1.68% |
| Return on Capital Employed (ROCE) | 2.65% | 3.21% | 2.62% | 9.65% | 1.84% |
| Return on Invested Capital (ROIC) | 2.38% | 2.49% | 2.05% | 7.48% | 1.58% |
| Return on Tangible Assets | 1.57% | 7.46% | 4.44% | 6.29% | 1.35% |
| Earnings Yield | 1.84% | 4.94% | 2.79% | 3.32% | 0.70% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.39 | 5.26 | 3.92 | 4.40 | 2.48 |
| Payables Turnover | 16.81 | 19.05 | 19.30 | 12.51 | 19.42 |
| Inventory Turnover | 1.41 | 1.79 | 1.61 | 1.19 | 2.23 |
| Fixed Asset Turnover | 0.26 | 0.32 | 0.31 | 0.28 | 0.41 |
| Asset Turnover | 0.20 | 0.21 | 0.18 | 0.18 | 0.21 |
| Working Capital Turnover Ratio | 3.84 | 1.50 | 1.45 | 1.95 | 1.20 |
| Cash Conversion Cycle | 305.48 | 253.79 | 300.66 | 361.80 | 292.07 |
| Days of Sales Outstanding | 67.66 | 69.35 | 93.21 | 83.03 | 147.21 |
| Days of Inventory Outstanding | 259.54 | 203.61 | 226.37 | 307.94 | 163.65 |
| Days of Payables Outstanding | 21.72 | 19.16 | 18.92 | 29.17 | 18.79 |
| Operating Cycle | 327.20 | 272.96 | 319.58 | 390.97 | 310.87 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.84 | 7.20 | 1.98 | 2.72 | 2.57 |
| Free Cash Flow Per Share | -3.26 | -0.72 | -7.45 | -7.99 | -4.54 |
| Dividend Paid and CapEx Coverage Ratio | 0.28 | 0.79 | 0.20 | 0.25 | 0.34 |
| Capital Expenditure Coverage Ratio | 0.36 | 0.91 | 0.21 | 0.25 | 0.36 |
| Operating Cash Flow Coverage Ratio | 0.22 | 0.87 | 0.21 | 0.54 | 130.06 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.56 | 0.18 | 0.33 | 0.32 |
| Free Cash Flow Yield | -6.70% | -0.80% | -7.70% | -9.37% | -6.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 54.11 | 20.27 | 35.85 | 30.15 | 144.14 |
| Price-to-Sales (P/S) Ratio | 4.33 | 7.10 | 8.77 | 10.34 | 9.27 |
| Price-to-Book (P/B) Ratio | 1.08 | 1.98 | 2.07 | 2.56 | 2.41 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -14.94 | -125.69 | -12.99 | -10.68 | -16.20 |
| Price-to-Operating Cash Flow Ratio | 26.42 | 12.58 | 48.97 | 31.36 | 28.59 |
| Price-to-Earnings Growth (PEG) Ratio | -0.68 | 0.31 | -7.80 | 0.07 | -1.70 |
| Enterprise Value Multiple | 16.53 | 12.35 | 20.68 | 19.67 | 53.79 |
| Enterprise Value | 6.75B | 11.23B | 10.67B | 9.68B | 7.68B |
| EV to EBITDA | 16.53 | 12.35 | 20.68 | 19.67 | 53.79 |
| EV to Sales | 5.02 | 7.37 | 8.86 | 10.76 | 8.89 |
| EV to Free Cash Flow | -17.31 | -130.43 | -13.11 | -11.11 | -15.53 |
| EV to Operating Cash Flow | 30.62 | 13.05 | 49.44 | 32.63 | 27.41 |
| Tangible Book Value Per Share | 44.89 | 45.52 | 46.30 | 32.80 | 29.91 |
| Shareholders’ Equity Per Share | 45.14 | 45.84 | 46.72 | 33.30 | 30.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.05 | 0.17 | 0.19 | 0.20 | 0.15 |
| Revenue Per Share | 11.24 | 12.75 | 11.03 | 8.25 | 7.93 |
| Net Income Per Share | 0.90 | 4.47 | 2.70 | 2.83 | 0.51 |
| Tax Burden | 1.05 | 0.83 | 0.81 | 0.80 | 0.85 |
| Interest Burden | 0.66 | 0.96 | 0.98 | 3.26 | 0.89 |
| Research & Development to Revenue | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 |
| SG&A to Revenue | 0.12 | 0.11 | 0.12 | 0.15 | 0.12 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Income Quality | 2.05 | 1.33 | 0.59 | 0.76 | 4.28 |
Currency in TWD
